XM does not provide services to residents of the United States of America.
S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Alcon, Rockwool, Zealand Pharma

EUROPE RESEARCH ROUNDUP- Alcon, Rockwool, Zealand Pharma Sept 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alcon, Rockwool and Zealand Pharma, on Tuesday. HIGHLIGHTS * Alcon AG ALCC.S : RBC raises to outperform from sector perform * Maersk MAERSKb.CO : JP Morgan resumes coverage with underweight rating; target DKK 8,575 * Rockwool ROCKB.CO : HSBC raises target price to DKK 3,200 from DKK 3,100 * Wizz Air WIZZ.L : JP Morgan cu
A
A
A
B
B
B
C
C
D
D
E
G
H
H
K
N
P
R
S
S
S
S
T
U
V
A
A
D
D
I
R

Big Pharma lacks motive to prep for new pandemics

BREAKINGVIEWS-Big Pharma lacks motive to prep for new pandemics The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 10 (Reuters Breakingviews) - Covid-19 underlined the critical importance of vaccines. The pandemic caused 16 million global deaths, and the current scare surrounding Mpox emphasises how citizens remain fearful of fresh outbreaks.
A
G
P
S

Political and General News Events from September 6

DIARY-Political and General News Events from September 6 Sept 6 (Reuters) - For other diaries, please see: Political and General News POL/DIARY Top Economic Events M/DIARY Emerging Markets Economic Events EMRG/DIARY Government Debt Auctions D/DIARY U.S. Federal Reserve FED/DIARY Today in Washington WASH/DIARY -------------------------------------------------------------------- This diary is filed daily.
S

Jefferies initiates Amicus Therapeutics with 'buy'

BUZZ-Jefferies initiates Amicus Therapeutics with 'buy' ** Jefferies initiates coverage on Amicus Therapeutics FOLD.O with "buy" rating and PT of $18, which implies a 54% upside to the stock's last close ** This marks the first bullish rating on the stock since May - LSEG data ** FOLD's therapy for Pompe disease can result in patients switching fro
S

How fake Ozempic batch numbers help criminal groups spread dangerous drugs

INSIGHT-How fake Ozempic batch numbers help criminal groups spread dangerous drugs Updates with preferred titles for U.S. Homeland Security and the agency's Rana Saoud in paragraphs 49 and 51 Knock-off batch numbers provide easy way to circulate fake drugs Fake Ozempic with a batch number destined for Egypt found in at least 10 countries Counterfeit Ozempic linked to hospitalizations By Patrick Wingrove Sept 5 (Reuters) - In December, Drew, a 36-year-old man from San Antonio, Texas, drove more t
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.